Candel Therapeutics, Inc. (NASDAQ:CADL) CTO Sells $275,871.96 in Stock

Candel Therapeutics, Inc. (NASDAQ:CADL) CTO Seshu Tyagarajan sold 31,278 shares of the business’s stock in a transaction that occurred on Monday, March 17th. The shares were sold at an average price of $8.82, for a total value of $275,871.96. Following the completion of the sale, the chief technology officer now directly owns 85,512 shares of the company’s stock, valued at approximately $754,215.84. The trade was a 26.78 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Seshu Tyagarajan also recently made the following trade(s):

• On Wednesday, January 15th, Seshu Tyagarajan sold 14,322 shares of Candel Therapeutics stock. The shares were sold at an average price of $7.22, for a total transaction of $103,404.84.

Candel Therapeutics Price Performance

Shares of NASDAQ:CADL opened at $8.90 on Thursday. The company has a 50 day moving average of $8.23 and a 200-day moving average of $7.00. Candel Therapeutics, Inc. has a one year low of $1.40 and a one year high of $14.60. The stock has a market cap of $289.04 million, a price-to-earnings ratio of -5.14 and a beta of -1.29.

Candel Therapeutics (NASDAQ:CADL) last issued its quarterly earnings data on Thursday, March 13th. The company reported ($0.40) EPS for the quarter, missing the consensus estimate of ($0.23) by ($0.17). Equities research analysts anticipate that Candel Therapeutics, Inc. will post -1.47 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on CADL shares. Citigroup began coverage on shares of Candel Therapeutics in a research note on Thursday, February 20th. They set a “buy” rating and a $25.00 price target on the stock. HC Wainwright reissued a “buy” rating and set a $19.00 price objective on shares of Candel Therapeutics in a report on Friday, March 14th. Bank of America assumed coverage on shares of Candel Therapeutics in a research report on Friday, February 7th. They set a “buy” rating and a $15.00 target price for the company. Finally, Canaccord Genuity Group increased their price objective on Candel Therapeutics from $20.00 to $25.00 and gave the company a “buy” rating in a research report on Wednesday, February 26th.

Institutional Trading of Candel Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in CADL. FMR LLC bought a new stake in Candel Therapeutics in the third quarter valued at approximately $46,000. MetLife Investment Management LLC acquired a new stake in Candel Therapeutics during the third quarter worth approximately $87,000. Atom Investors LP bought a new position in shares of Candel Therapeutics in the third quarter worth $103,000. State Street Corp increased its holdings in Candel Therapeutics by 4.1% in the 3rd quarter. State Street Corp now owns 492,005 shares of the company’s stock valued at $3,410,000 after buying an additional 19,207 shares during the period. Finally, Barclays PLC raised its position in Candel Therapeutics by 327.1% during the third quarter. Barclays PLC now owns 28,688 shares of the company’s stock valued at $199,000 after purchasing an additional 21,971 shares in the last quarter. 13.93% of the stock is owned by institutional investors.

About Candel Therapeutics

Candel Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma.